0001628280-23-034376.txt : 20231013 0001628280-23-034376.hdr.sgml : 20231013 20231013164244 ACCESSION NUMBER: 0001628280-23-034376 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231007 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20231013 DATE AS OF CHANGE: 20231013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: American Oncology Network, Inc. CENTRAL INDEX KEY: 0001839998 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40177 FILM NUMBER: 231325464 BUSINESS ADDRESS: STREET 1: 14543 GLOBAL PKWY #110 CITY: FORT MYERS STATE: FL ZIP: 33913 BUSINESS PHONE: 833-886-1725 MAIL ADDRESS: STREET 1: 14543 GLOBAL PKWY #110 CITY: FORT MYERS STATE: FL ZIP: 33913 FORMER COMPANY: FORMER CONFORMED NAME: Digital Transformation Opportunities Corp. DATE OF NAME CHANGE: 20210111 8-K 1 aonc-20231007.htm 8-K aonc-20231007
0001839998FALSE00018399982023-10-072023-10-070001839998us-gaap:CommonStockMember2023-10-072023-10-070001839998us-gaap:WarrantMember2023-10-072023-10-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 7, 2023
American Oncology Network, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-4017785-3984427
(State or other jurisdiction of
 incorporation or organization)
(Commission File Number)(I.R.S. Employer
Identification Number)
14543 Global Parkway, Suite 110
Fort Myers, FL
33913
(Address of principal executive offices)(Zip Code)
(833) 886-1725
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each class
Trading
 Symbol(s)
Name of each exchange on
 which registered
Class A common stock, par value $0.0001, per shareAONCThe Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stockAONCWThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On October 7, 2023, Shalin R. Shah, DO, Vipul Patel, MD, and Vance M. Wright-Browne, MD (collectively, the “Resigning Directors”), each notified American Oncology Network, Inc. (the “Company”) of their respective intentions to resign as directors of the Company, effective as of October 13, 2023. The Resigning Directors’ resignations were not the result of any dispute or disagreement with the Company or the Company’s Board of Directors on any matter relating to the operations, policies or practices of the Company.




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 13, 2023
AMERICAN ONCOLOGY NETWORK, INC.
By:/s/ Todd Schonherz
Name:Todd Schonherz
Title:Chief Executive Officer

EX-101.SCH 2 aonc-20231007.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 aonc-20231007_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 4 aonc-20231007_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Former Address Former Address [Member] Document Period End Date Document Period End Date Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Central Index Key Entity Central Index Key Equity Components [Axis] Equity Components [Axis] Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Document Information [Line Items] Document Information [Line Items] Local Phone Number Local Phone Number Trading Symbol Trading Symbol Address Type [Domain] Address Type [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Warrant Warrant [Member] Document Type Document Type Amendment Flag Amendment Flag Entity Ex Transition Period Entity Ex Transition Period Document Information [Table] Document Information [Table] Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 aonc-20231007_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 07, 2023
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Oct. 07, 2023
Entity Registrant Name American Oncology Network, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40177
Entity Tax Identification Number 85-3984427
Entity Address, Address Line One 14543 Global Parkway
Entity Address, Address Line Two Suite 110
Entity Address, City or Town Fort Myers
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33913
City Area Code 833
Local Phone Number 886-1725
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Central Index Key 0001839998
Amendment Flag false
Common Stock  
Document Information [Line Items]  
Title of 12(b) Security Class A common stock, par value $0.0001, per share
Trading Symbol AONC
Security Exchange Name NASDAQ
Warrant  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Class A common stock
Trading Symbol AONCW
Security Exchange Name NASDAQ
XML 7 aonc-20231007_htm.xml IDEA: XBRL DOCUMENT 0001839998 2023-10-07 2023-10-07 0001839998 us-gaap:CommonStockMember 2023-10-07 2023-10-07 0001839998 us-gaap:WarrantMember 2023-10-07 2023-10-07 0001839998 false 8-K 2023-10-07 American Oncology Network, Inc. DE 001-40177 85-3984427 14543 Global Parkway Suite 110 Fort Myers FL 33913 833 886-1725 false false false false Class A common stock, par value $0.0001, per share AONC NASDAQ Warrants, each whole warrant exercisable for one share of Class A common stock AONCW NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 24 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.aoncology.com/role/Cover Cover Cover 1 false false All Reports Book All Reports aonc-20231007.htm aonc-20231007.xsd aonc-20231007_def.xml aonc-20231007_lab.xml aonc-20231007_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aonc-20231007.htm": { "nsprefix": "aonc", "nsuri": "http://www.aoncology.com/20231007", "dts": { "inline": { "local": [ "aonc-20231007.htm" ] }, "schema": { "local": [ "aonc-20231007.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "aonc-20231007_def.xml" ] }, "labelLink": { "local": [ "aonc-20231007_lab.xml" ] }, "presentationLink": { "local": [ "aonc-20231007_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 34, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://www.aoncology.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20231007.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20231007.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "FormerAddressMember", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Former Address", "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r6", "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant", "label": "Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001628280-23-034376-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-034376-xbrl.zip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